These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis. Kawamura M, Konishi N, Hiroe K, Shofuda K, Imaeda Y, Fujimoto T, Kubo K. J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831 [Abstract] [Full Text] [Related]
4. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. Wong PC, Crain EJ, Watson CA, Xin B. J Thromb Haemost; 2009 Aug; 7(8):1313-20. PubMed ID: 19500242 [Abstract] [Full Text] [Related]
5. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. Sinha U, Ku P, Malinowski J, Zhu BY, Scarborough RM, Marlowe CK, Wong PW, Lin PH, Hollenbach SJ. Eur J Pharmacol; 2000 Apr 21; 395(1):51-9. PubMed ID: 10781674 [Abstract] [Full Text] [Related]
6. Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Chu V, Brown K, Colussi D, Gao J, Bostwick J, Kasiewski C, Bentley R, Morgan S, Guertin K, Pauls HW, Gong Y, Zulli A, Perrone MH, Dunwiddie CT, Leadley RJ. Thromb Res; 2001 Aug 15; 103(4):309-24. PubMed ID: 11562341 [Abstract] [Full Text] [Related]
7. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding. Hu X, Xiao Y, Yu C, Zuo Y, Yang W, Wang X, Gu B, Li J. Eur J Pharmacol; 2018 Apr 15; 825():85-91. PubMed ID: 29475063 [Abstract] [Full Text] [Related]
8. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T. J Thromb Haemost; 2008 Sep 15; 6(9):1542-9. PubMed ID: 18624979 [Abstract] [Full Text] [Related]
15. Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor. Chi L, Pen YW, Potoczak R, Gibson G, Hicks G, Mertz TE, Janiczek N, Juneau PL, Gallagher K, Leadley R. Pharmacology; 2002 Feb 01; 64(2):76-83. PubMed ID: 11803247 [Abstract] [Full Text] [Related]
16. Rivaroxaban: a new oral factor Xa inhibitor. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Arterioscler Thromb Vasc Biol; 2010 Mar 01; 30(3):376-81. PubMed ID: 20139357 [Abstract] [Full Text] [Related]